Skip to content

CAPLA trial: Catheter Ablation for persistent atrial fibrillation: A Multicentre randomised trial of Pulmonary vein antral isolation (PVAI) vs PVAI with posterior left atrial wall isolation (PWI).

CAPLA trial: Catheter Ablation for persistent atrial fibrillation: A Multicentre randomised trial of Pulmonary vein antral isolation (PVAI) vs PVAI with posterior left atrial wall isolation (PWI).

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12616001436460
Acronym
CAPLA study
Enrollment
338
Registered
2016-10-14
Start date
2018-07-25
Completion date
2021-03-15
Last updated
2022-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

What is known? PVAI for AF is the standard of care in people with symptomatic paroxysmal AF (class I indication) but the next step in ablation for people with persistent AF is unknown. A major international landmark trial has yielded neutral results with some forms of additional ablation but the effect of PWI + PVAI has not been formally assessed in a multicentre randomised trial. What this study adds? Multicentre randomised trial assessing the effect of adding PWI to PVAI in persistent AF on 12-month arrhythmia free survival. Primary Endpoints Recurrence of atrial tachyarrhythmia (AT/AF/AFL) for >30 seconds. Single procedure success rate off antiarrhythmic drugs at 12 months. Secondary Endpoints Procedural duration Fluoroscopy time Requirement for antiarrhythmic medication beyond 3 months Success after multiple procedures at 12 months off AADs Success after multiple procedures at 12 months on AADs Complication rates at 12 months (including pulmonary vein stenosis, perforation, tamponade, stroke) AFEQT quality of life score AF6 score Canadian Cardiovascular Society Severity in AF (CCS-SAF) score New York Heart Association (NYHA) score Echocardiographic dimensions (LA dimensions and volume, left ventricular end-systolic and end-diastlic dimensions)

Interventions

1. name / Phrase: CAPLA trial: Catheter Ablation for persistent atrial fibrillation: A Multicentre randomised trial of Pulmonary vein isolation (PVI) vs PVI with post Left Atrial wall isolation (PWI). 2. Goal / Elements: Atrial fibrillation (AF) ablation also known as pulmonary vein isolation (PVI) has become standard practice and recommended for patients with symptomatic paroxysmal AF (PAF). However, the optimal ablation strategy for patients with persistent atrial fibrillation (PsAF) is not k

1. name / Phrase: CAPLA trial: Catheter Ablation for persistent atrial fibrillation: A Multicentre randomised trial of Pulmonary vein isolation (PVI) vs PVI with post Left Atrial wall isolation (PWI). 2. Goal / Elements: Atrial fibrillation (AF) ablation also known as pulmonary vein isolation (PVI) has become standard practice and recommended for patients with symptomatic paroxysmal AF (PAF). However, the optimal ablation strategy for patients with persistent atrial fibrillation (PsAF) is not known. Current guidelines recommend use of PVI only in this patient population which we also know is ineffective. Recent evidence has shown that posterior wall isolation (PWI) in addition to PVI may offer benefit in patients with PsAF. Hence we have designed this randomised trial comparing PVI alone vs PVI + PWI and assess 12 month outcomes. 3. Materials: This trial incorporates standard practice for patients with PsAF. All patients will be seen at our arrhythmia clinic with written information provided about atrial fibrillation and the management options available as per routine care. If they are selected for intervention based on clinical and standard management guidelines, they will then be offered enrollment in our trial. If they choose to, addition written information will be provided at that point about the interventions. All trial patients will be followed up closely at 3, 6 and 12 months after intervention. 4. Procedures: Standard / Routine pulmonary vein isolation will be performed in all patients. The additional step in those randomised to the posterior wall isolation will involve a roof and inferior line that is also considered routine care in patients with persistent atrial fibrillation. The standard procedure involves minimally invasive procedure in which patient is taken to the cardiac catheter laboratory. Procedure performed under general anaesthesia. femoral venous access obtained through with catheters are advanced into the heart. The pulmonary veins in the left atrium are targeted with radio frequency ablation using special catheters that can deliver radiofrequency energy to the atrial tiuuse. At the end of the procedure, all sheaths and catheters removed from body. 5. Care provided by Cardiologist and Electrophysiologists who will be looking after the patients regardless of whether they are part of the trial. 6 & 7. Modes of delivery locations: Care and intervention will be provided directly. Location will be tertiary hospitals. 8. Intervention: Interventions will be performed once as part of the trial. Subsequent intervention will be based on patients’ clinical indication and the physician recommendation. Approximate duration of procedure in the PVI group is 2.5 hours. The PVI + PWI group is expected to be slightly longer at approximately 3 hours. 9 & 10. Tailoring or modification: During the ablation, the proceduralist will decide if any additional intervention is clinically necessary or recommended as part of patient care. Any intervention required for the benefit of the patient will be undertaken as needed.

Sponsors

Alfred Hospital
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Patients aged 18 to 80 yeasr old with symptomatic documented persistent AF who have trialled and failed to antiarrhythmic therapy

Exclusion criteria

Paroxysmal AF. Patients with permanent or chronic persistent AF > 18months. AF secondary to reversible cause such as thyrotoxicosis or severe untreated sleep apnoea. Patients with contra indication to anticoagulation. Creatinine >200, End stage renal or hepatic failure. Severe valvular heart disease or cyanotic congenital heart disease.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 10, 2026